Pharma & CDMO — India
Global generics cycle + India CDMO opportunity + domestic chronic-therapy growth.
The thesis
Indian pharma has three distinct stories: (1) US generics — Sun, Cipla, Dr Reddy's, Lupin — benefiting from US FDA compliance + new launches + shortage pricing, (2) CDMO/CRO — Divi's, Laurus, Syngene, Piramal Pharma — on biotech funding revival and China+1 supply-chain diversification, (3) domestic chronic therapy — Mankind, Torrent, Alkem — on growing prescription base. The Indian pharma sector is trading at historically attractive multiples after 2015-2020 derating.
Listed constituents
The textbook names with pure-play or meaningful exposure. Not a weighted index — sort by market-cap on /scanner.
| Symbol | Company | Role |
|---|---|---|
| SUNPHARMA | Sun Pharmaceutical | Largest Indian pharma, specialty US + Ilumya |
| CIPLA | Cipla | US + respiratory + India |
| DRREDDY | Dr Reddy's Labs | US generics + biosimilars |
| LUPIN | Lupin | US generics + respiratory |
| APOLLOHOSP | Apollo Hospitals | Healthcare services + pharmacy |
| DIVISLAB | Divi's Laboratories | API + CDMO leader |
| LAURUSLABS | Laurus Labs | API + CDMO + ARV |
| SYNGENE | Syngene International | CRO / CDMO |
| PIRAMALPHAR | Piramal Pharma | Contract manufacturing |
| ALKEM | Alkem Labs | Domestic chronic + acute |
| TORNTPHARM | Torrent Pharmaceuticals | Domestic + US |
| MANKIND | Mankind Pharma | Domestic chronic pharma |
| GLAND | Gland Pharma | Injectables CDMO |
| ZYDUSLIFE | Zydus Lifesciences | US + NCE pipeline |
Tailwinds
- • US generic pricing stabilising after 2017-22 deflation
- • Biosecure Act + China+1 → CDMO wins for Indian contract manufacturers
- • Biotech funding recovery driving CDMO order intake
- • Indian chronic therapy growing 10-12% YoY; prescription penetration still low
Risks
- • US FDA import-alert risk for any facility
- • USD/INR reversal would hurt US-heavy names
- • Generic pricing resumes decline if new entrants intensify
- • CDMO order cycle is lumpy; 1 quarter can make/break a year
Stress-test the narrative
Use these tools on the constituents above to sanity-check the thesis before you size exposure.
Want a deeper dive on Pharma & CDMO — India?
Axel can rank these constituents by valuation, sentiment, and 1-year forward estimates — and explain why each name is up or down today.
Primary sources
Other themes
Research tool · not investment advice.
Axel Markets is an information + analytics product. We are not a SEBI-registered Research Analyst (RA) or Investment Adviser (IA). Nothing on this page is a buy, sell, or hold recommendation. Past performance is not indicative of future returns. Verify all data against the authoritative source (NSE, BSE, AMFI, SEBI, company RHP / factsheet) before acting. Theme snapshot as of 2026-04. Constituent weights shift; cross-check live index composition before sizing. Tailwinds + risks are editorial summaries of publicly reported trends, not forecasts. Past performance does not predict future returns. Not investment advice.